Guardant Health Stock Price, News & Analysis

Guardant Health has priced an offering of $1 billion in 0% convertible senior notes due 2027, set to settle on November 19, 2020. The notes will not accrue interest and have an initial conversion rate of 7.1523 shares per $1,000, representing a conversion price of around $139.82, a 34% premium over its recent stock price. The company expects net proceeds of approximately $984.3 million, intended for corporate purposes, including research and development and potential acquisitions. Additionally, capped call transactions are in place to reduce dilution from the notes' conversion.

Guardant Health (Nasdaq: GH) announced a private offering of $1 billion in convertible senior notes due 2027, with an additional $150 million option for initial purchasers. The notes will mature on November 15, 2027, and can be converted into cash or stock. Proceeds will fund capped call transactions and general corporate purposes, including R&D and potential acquisitions. This offering is subject to market conditions, and the notes are not registered under the Securities Act. Guardant Health is a leader in precision oncology, focusing on innovative blood tests for cancer detection.

Guardant Health (GH) reported a 23% revenue increase to $74.6 million for Q3 2020, driven by a 16% rise in precision oncology revenue ($60.4 million). Development services surged 63% to $14.2 million. Clinical test volume rose 28% to 16,950, but biopharmaceutical tests fell 42% to 3,071. The company received FDA approval for Guardant360® CDx, the first liquid biopsy for comprehensive cancer profiling. Despite a gross profit rise to $53.4 million, operating expenses ballooned 113% to $127.6 million, leading to a net loss of $77.7 million ($0.78 per share). Guidance for 2020 remains unprovided due to COVID-19 uncertainties.

Guardant Health, Inc. (Nasdaq: GH) will release its third-quarter 2020 financial results on November 5, 2020, after market closure. A conference call will follow at 1:30 p.m. PT. Investors can access the live audio webcast in the 'Investors' section of the company website. Guardant Health specializes in precision oncology, providing advanced blood tests like Guardant360 and GuardantOMNI to improve cancer patient outcomes and reduce healthcare costs. The company focuses on all cancer care stages, including early detection and selection of treatments for advanced cancer patients.

Guardant Health, Inc. (Nasdaq: GH) has completed a public offering of 7.7 million shares of common stock, priced at $102.00 per share, including 700,000 shares from the underwriter's option. Notably, Guardant Health did not sell any shares nor receive proceeds from this offering, which was conducted by SoftBank Investment Advisers. The offering was made under an automatic shelf registration statement filed with the SEC, which became effective upon filing. J.P. Morgan Securities LLC served as the book-running manager for this offering.

Guardant Health has announced a public offering of 7,000,000 shares of its common stock priced at $102.00 per share, with the offering managed by J.P. Morgan Securities LLC. The shares are being sold by SoftBank Investment Advisers, and Guardant Health will not receive any proceeds from this sale. An additional option for underwriters to purchase up to 700,000 shares is also available. The offering is expected to close on October 9, 2020, pending customary closing conditions. This public offering is registered under Form S-3 with the SEC.

Guardant Health (Nasdaq: GH) has initiated a public offering of 7,000,000 shares of its common stock, which will be sold exclusively by SoftBank Investment Advisers. An additional 700,000 shares may be available through an underwriter's option. Guardant Health is not participating in the sale and will not receive any proceeds. The offering is under an automatic shelf registration statement with the SEC and is subject to market conditions. J.P. Morgan Securities LLC is the sole book-running manager for the offering.

Guardant Health (Nasdaq: GH) has released study findings from the SCRUM-Japan GOZILA trial, indicating that its Guardant360 liquid biopsy significantly enhances clinical trial enrollment for advanced gastrointestinal cancer. The study shows a 67% reduction in screening duration (median of 11 days vs. 33 days) and a 132% improvement in enrollment rates (9.5% vs. 4.1%) compared to traditional tissue genotyping. Furthermore, Guardant360 provides non-inferior treatment outcomes, detecting more actionable genomic alterations without compromising patient response rates or progression-free survival.

Guardant Health (Nasdaq: GH) will participate in the Morgan Stanley Virtual Healthcare Conference on September 15 at 8:45 a.m. Pacific Time. The event includes a fireside chat with company management, accessible via a live and archived webcast on their website. Guardant Health is a leader in precision oncology, utilizing proprietary blood tests and data analytics to enhance cancer treatment. Their offerings include the Guardant360® and GuardantOMNI® tests, primarily for advanced cancer patients, and the LUNAR program aimed at early-stage cancer detection and treatment.